From Wikipedia, the free encyclopedia
Serotonin-norepinephrine-dopamine reuptake inhibitor
Centanafadine
|
|
Legal status |
|
---|
|
(1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
|
Formula | C15H15N |
---|
Molar mass | 209.292 g·mol−1 |
---|
3D model (
JSmol) | |
---|
C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4
|
InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1 Key:HKHCSWPSUSWGLI-CABCVRRESA-N
|
Centanafadine
[1]
Site |
IC50 (nM) |
Action |
Ref
|
SERTTooltip Serotonin transporter |
83 nM |
Blocker |
[1]
|
NETTooltip Norepinephrine transporter |
6 nM |
Blocker |
[1]
|
DATTooltip Dopamine transporter |
38 nM |
Blocker |
[1]
|
Centanafadine (
INN) (former developmental code name EB-1020) is a
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its
development with
Euthymics Bioscience after they acquired
DOV Pharmaceutical. It was developed as a treatment for
attention-deficit hyperactivity disorder (ADHD) and inhibits the
reuptake of
norepinephrine,
dopamine, and
serotonin with a ratio of 1:6:14, respectively.
[1]
[2]
[3]
[4] In 2011,
Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.
[5]
[6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.
[7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions.
[8]
[9]
[10]
See also
References
- ^
a
b
c
d
e
"Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.
-
^
"3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.
-
^
"EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance. Archived from
the original (PDF) on 2015-11-17. Retrieved 2015-11-14.
-
^ Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI (June 2012). "Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder". Synapse. 66 (6): 522–32.
doi:
10.1002/syn.21538.
PMID
22298359.
S2CID
38850652.
-
^
"Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.
-
^
"EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.
-
^
"Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.
-
^
"Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.[
permanent dead link]
-
^ Otsuka Pharmaceutical Development & Commercialization, Inc. (2021-09-17).
"A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder".
-
^ Gunduz-Bruce H (2018-09-26).
"SAGE-217 in major depressive disorder: a multicenter, randomized, double-blind, Phase 2 placebo-controlled trial".
doi:
10.26226/morressier.5b68175eb56e9b005965c44b.
S2CID
266120058. Retrieved 2023-06-26.
External links
|
---|
DATTooltip Dopamine transporter (
DRIsTooltip Dopamine reuptake inhibitors) | |
---|
NETTooltip Norepinephrine transporter (
NRIsTooltip Norepinephrine reuptake inhibitors) | | | | | | |
- Others:
Antihistamines (e.g.,
brompheniramine,
chlorphenamine,
pheniramine,
tripelennamine)
-
Antipsychotics (e.g.,
loxapine,
ziprasidone)
-
Arylcyclohexylamines (e.g.,
ketamine,
phencyclidine)
-
Dopexamine
-
Ephenidine
-
Ginkgo biloba
-
Indeloxazine
-
Nefazodone
-
Opioids (e.g.,
desmetramadol,
methadone,
pethidine (meperidine),
tapentadol,
tramadol,
levorphanol)
|
|
---|
SERTTooltip Serotonin transporter (
SRIsTooltip Serotonin reuptake inhibitors) | | | | |
- Others:
A-80426
-
Amoxapine
-
Antihistamines (e.g.,
brompheniramine,
chlorphenamine,
dimenhydrinate,
diphenhydramine,
mepyramine (pyrilamine),
pheniramine,
tripelennamine)
-
Antipsychotics (e.g.,
loxapine,
ziprasidone)
-
Arylcyclohexylamines (e.g.,
3-MeO-PCP,
esketamine,
ketamine,
methoxetamine,
phencyclidine)
-
Cyclobenzaprine
-
Delucemine
-
Dextromethorphan
-
Dextrorphan
-
Efavirenz
-
Hypidone
-
Medifoxamine
-
Mesembrine
-
Mifepristone
-
MIN-117 (WF-516)
-
N-Me-5-HT
-
Opioids (e.g.,
dextropropoxyphene,
methadone,
pethidine (meperidine),
levorphanol,
tapentadol,
tramadol)
-
Roxindole
|
|
---|
VMATsTooltip Vesicular monoamine transporters | |
---|
Others | |
---|
|